A Study to Evaluate the Long Term Safety and Efficacy of Bimekizumab in Subjects With Ankylosing Spondylitis

Part of paid clinical trials in Sarasota, Florida.

Sponsor
UCB Biopharma SRL
Study ID
NCT03355573
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Bimekizumab — DRUG
    Bimekizumab at a prespecified dose.

Study Details

This is a study to assess the long term safety and tolerability of bimekizumab in subjects with ankylosing spondylitis

Key Dates

Start date
Nov 28, 2017
Status verified
Nov 2024
Primary completion
Oct 19, 2022
Completion
Oct 19, 2022

Study Design

Enrollment
255 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Bimekizumab
    Subjects will receive bimekizumab up to 4 years.

Primary Outcome Measure

Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study [ Time Frame: From Entry Visit (Visit 1) until Safety Follow Up (up to Week 224) ]

Locations (3)

FacilityCityStateZIPSite coordinators
As0009 30SarasotaFlorida34239-
AS0009 1DuncansvillePennsylvania16635-
AS0009 6DallasTexas75231-

Find similar trials in Sarasota, FL

By research site
As0009 30· Sarasota, FLAS0009 1· Duncansville, PAAS0009 6· Dallas, TX

Related Studies